Matinas BioPharma (NYSEAMERICAN:MTNB) Releases Quarterly Earnings Results

Matinas BioPharma (NYSEAMERICAN:MTNB) released its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share for the quarter, Yahoo Finance reports.

Matinas BioPharma Price Performance

Shares of NYSEAMERICAN MTNB opened at $0.27 on Friday. Matinas BioPharma has a 1 year low of $0.11 and a 1 year high of $0.89.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC increased its stake in shares of Matinas BioPharma by 949.1% during the 2nd quarter. Jane Street Group LLC now owns 162,730 shares of the company’s stock worth $129,000 after purchasing an additional 147,219 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Matinas BioPharma in the fourth quarter worth about $120,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Matinas BioPharma in the third quarter valued at approximately $98,000. Private Advisor Group LLC purchased a new stake in shares of Matinas BioPharma during the 1st quarter valued at approximately $92,000. Finally, Renaissance Technologies LLC boosted its holdings in Matinas BioPharma by 42.0% in the 1st quarter. Renaissance Technologies LLC now owns 171,929 shares of the company’s stock worth $81,000 after buying an additional 50,833 shares during the period. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.